Ivor (Bemiparin Sodium)

Bemiparin Sodium is indicated for several thromboembolic conditions, acting primarily to prevent clot formation.

• Deep vein thrombosis (prevention): reduces incidence of postoperative DVT in surgical patients.
• Deep vein thrombosis (treatment): facilitates resolution of acute DVT by inhibiting further clot propagation.
• Pulmonary embolism (prevention): lowers risk of PE in high‑risk medical patients.
• Thromboembolic prophylaxis in medical patients: prevents clot events in immobilised or critically ill individuals.

• Bemiparin Sodium binds to antithrombin III, enhancing its inhibitory activity against activated factor Xa and, to a lesser extent, thrombin (factor IIa). This accelerated inhibition disrupts the conversion of prothrombin to thrombin and the generation of fibrin, leading to reduced clot formation while preserving a degree of hemostatic balance. The selective factor Xa inhibition provides anticoagulation with a relatively predictable pharmacokinetic profile.

Bemiparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain or erythema: mild discomfort or redness at the injection site.
• Bruising or hematoma: localized bleeding under the skin.
• Minor bleeding: such as epistaxis or gum bleeding.
• Nausea: transient gastrointestinal upset.
• Headache: mild to moderate intensity.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Major bleeding: gastrointestinal, intracranial or surgical site hemorrhage.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet count drop.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Skin necrosis: severe local tissue damage.
• Spinal or epidural hematoma: risk after neuraxial procedures.
• Thrombosis paradoxically: rare clot formation despite therapy.

Before initiating Bemiparin Sodium, several precautionary measures should be considered to minimise risk.

• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Hepatic impairment: use with caution in severe liver disease due to altered metabolism.
• Concomitant anticoagulants or antiplatelet agents: increased bleeding risk; monitor coagulation parameters.
• Recent surgery or trauma: assess bleeding risk before administration.
• Pregnancy: category B; use only if potential benefit justifies potential risk to the fetus.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Bemiparin Sodium can interact with several medicines, affecting its anticoagulant effect or bleeding risk.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulation may cause severe bleeding.
• Antiplatelet drugs (aspirin, clopidogrel): heightened bleeding tendency.
• Thrombolytic agents (alteplase, streptokinase): risk of uncontrolled hemorrhage.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding.
• Neuraxial anesthesia or spinal puncture: potential for spinal hematoma.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may potentiate hypotensive effects when combined with bleeding.
• Corticosteroids: can exacerbate gastrointestinal bleeding.
• Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding risk.
• Selective COX‑2 inhibitors (celecoxib): similar bleeding considerations.
• Heparin flush solutions: cumulative heparin exposure may affect platelet counts.